Oncothyreon ($ONTY) initiates phase 1 trial of ONT-10 ($4.80).
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. They are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. The pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications.
- The company announced that the first patient has been enrolled in a Phase 1 trial of ONT-10
- The Phase 1 trial is designed to evaluate the safety and immunogenicity of ONT-10 in patients with cancers which commonly express MUC1
- The Phase 1 trial of ONT-10 consists of two parts
- Part 1 will study a dose escalation schedule in up to 48 patients to determine the maximally tolerated and/or recommended dose of ONT-10 administered either once every other week or once every week over an 8 week period
- Part 2 will further investigate the safety of ONT-10 at the maximally tolerated or recommended dose in up to 15 additional patients at the weekly and/or biweekly schedule
The ability of ONT-10 to induce both a humoral and a cellular immune response will be investigated in both parts of the study.
Daily Dose Conclusion: This is an interesting data point in the wake of StimuVax delays which were not perceived well by the marketplace.
